ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ESTEVE-Acq-TerSera

More Like This

PR Newswire associated0

ESTEVE INCREASES NET REVENUE BY 5% AND REAFFIRMS STRATEGY TOWARDS BECOMING A HIGHLY SPECIALIZED COMPANY

PR Newswire associated0

ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities

PR Newswire associated0

ESTEVE to acquire medicine to treat medullary thyroid cancer

PR Newswire associated0

ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Business Wire logo

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America